6009-98-9
6009-98-9 structure
- Name: Taurochenodeoxycholic acid sodium salt
- Chemical Name: Sodium taurochenodeoxycholate
- CAS Number: 6009-98-9
- Molecular Formula: C26H44NNaO6S
- Molecular Weight: 521.685
- Catalog: Signaling Pathways Apoptosis Apoptosis
- Create Date: 2018-09-01 17:44:58
- Modify Date: 2024-01-10 15:46:25
-
Taurochenodeoxycholic acid sodium salt (12-Deoxycholyltaurine sodium salt) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties[1][2].
| Name | Sodium taurochenodeoxycholate |
|---|---|
| Synonyms |
2-(((3α,5β,7α)-3,7-Dihydroxy-24-oxocholan-24-yl)amino)ethanesulfonic acid monosodium salt
Ethanesulfonic acid, 2-[[(3α,5β,7α,8ξ)-3,7-dihydroxy-24-oxocholan-24-yl]amino]-, sodium salt (1:1) Ethanesulfonic acid, 2-(((3α,5β,7α)-3,7-dihydroxy-24-oxocholan-24-yl)amino)-, monosodium salt taurochenodeoxycholic acid sodium salt Sodium 2-{[(3α,5β,7α,8ξ)-3,7-dihydroxy-24-oxocholan-24-yl]amino}ethanesulfonate MFCD00036745 |
| Description | Taurochenodeoxycholic acid sodium salt (12-Deoxycholyltaurine sodium salt) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties[1][2]. |
|---|---|
| Related Catalog | |
| Target |
Human Endogenous Metabolite |
| In Vitro | Taurochenodeoxycholic acid dramatically improves the apoptosis rate of NR8383 cells in a concentration-dependent manner. In the meantime, Taurochenodeoxycholic acid significantly augments PKC mRNA levels, activities and increases JNK, caspase-3 and caspase-8 mRNA expression levels, activities[1]. |
| In Vivo | Taurochenodeoxycholic acid (0.05, 0.1g/kg) decreases the pulmonary coefficient in the model mice and reduces the pathological damages on their lungs; it can decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice and has no significant effects on MMP2[2]. Taurochenodeoxycholic acid significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation[3]. Taurochenodeoxycholic acid significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats[4]. |
| References |
| Density | 1.164 g/mL at 25 °C(lit.) |
|---|---|
| Boiling Point | 215 °C(lit.) |
| Molecular Formula | C26H44NNaO6S |
| Molecular Weight | 521.685 |
| Flash Point | 195 °F |
| Exact Mass | 521.278687 |
| PSA | 135.14000 |
| LogP | 4.52640 |
| Index of Refraction | n20/D 1.558(lit.) |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
